Black Diamond Therapeutics' BDTX-1535 Demonstrates Promising Results in Lung Cancer Treatment
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows potential as a new option in cancer therapy.
Background of the Study
BDTX-1535 is an innovative drug designed to target mutations in lung cancer that have shown resistance to existing therapies, including those developed by AstraZeneca. This study focuses on patients whose cancer has relapsed after prior treatments.
Study Results
- Initial Phase 2 trial results show a 36% response rate.
- Patients exhibited prolonged durability of response.
Conclusion
The findings underscore the significance of BDTX-1535 in the ongoing development of therapies for lung cancer.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.